PEPTIDE THERAPEUTICS IN METABOLIC DISORDERS MARKET ANALYSIS

Peptide Therapeutics in Metabolic Disorders Market, By Route of Administration (Intravenous, Oral, Nasal, and Others), By Synthesis Technology (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis, and Hybrid Technology), and By Distribution Channels (Hospitals, Specialty Clinics, Retail Pharmacy, and Online Pharmacy) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Sep 2024
Code : CMI2003
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Key players in the Peptide Therapeutics in Metabolic Disorders Market:

Some of the key players operating in the market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S.

Peptide Therapeutics In Metabolic Disorders Market Report Snapshots